Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States

Documenti analoghi

• Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial
  di: Ayodele Odutayo, et al.
  Pubblicazione: (2024)
• Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
  di: Kevin Cowart, et al.
  Pubblicazione: (2025)
• Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
  di: Linong Ji, et al.
  Pubblicazione: (2024)
• Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
  di: Jean‐François Yale, et al.
  Pubblicazione: (2024)
• Effectiveness and safety of once‐weekly subcutaneous semaglutide versus other glucose‐lowering agents in real‐world patients with type 2 diabetes: A retrospective, observational post‐marketing study
  di: Chenyang Shi, et al.
  Pubblicazione: (2024)